摘要:
Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R1-R5 have the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
摘要:
Disclosed are new dihydropteridinones of general formula (I) whereby the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropteridinones and their use as pharmaceutical compositions.
摘要:
Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.
摘要:
Disclosed are compounds of general formula (I), wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.
摘要翻译:公开了通式(I)的化合物,其中基团A,R 1,R 2,R a和R b 具有权利要求和说明书中给出的含义,互变异构体,外消旋体,对映异构体,非对映异构体及其混合物,以及任选的药理学上可接受的酸加成盐,溶剂合物和水合物,以及制备这些噻唑基 - 喹唑啉及其作为药物组合物的用途。
摘要:
Disclosed are 6-formyl-tetrahydropteridines of the formula (I) wherein the groups R1 to R6 have the meanings given in the claims and specification, the isomers thereof, methods of preparing these 6-formyl-tetrahydropteridines and their use as medicaments.
摘要:
Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R1-R5 have the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
摘要:
The invention relates to compounds of general formula 1 wherein n, A, B, D, L, R1, R2, R3 and R4 may have the meanings given in the claims and in the specification, processes for preparing them, and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.
摘要翻译:本发明涉及通式1的化合物,其中n,A,B,D,L,R 1,R 2,R 3和 R 4可以具有权利要求书和说明书中给出的含义,其制备方法及其作为药物组合物的用途,特别是作为用于治疗呼吸道疾病的药物组合物。
摘要:
The present invention relates to new dihydropteridinones of the formula (I) wherein the groups X, R1, R2, R3, R4, R5 and R7 have the meanings given in the claims and the specification, the isomers thereof, processes and intermediates for preparing these dihydropteridinones as well as the use thereof as pharmaceutical compositions.
摘要:
This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3, R3a have meanings given in the description.